ライフサイエンスコーパス: CDAI

1 CDAI and goal interval scores (GIS) were assessed at wee

2 CDAI was used to assess response.

3 CDAI, CRP, fecal calprotectin and VCE Lewis inflammatory

4 CDAI-70 response rates at week 6 were similar for CT-P13

5 9 on placebo (99.5% CI 20.6-36.8; p<0.0001); CDAI clinical remission-composite was reached in 263 (45

6 maintenance trial was remission at week 44 (CDAI score <150).

7 Index (CDAI) clinical remission at week 52 (CDAI clinical remission-composite).

8 s entered a sustained remission defined by a CDAI < or =150.

9 east 100 points) and remission (defined by a CDAI score of 150 or less) were secondary end points.

10 cent, P=0.01) and of remission, defined by a CDAI score of 150 points or less on day 57 (40 percent v

11 Ten vs 2 patients had a CDAI less than 150 (remission) at the final evaluation,

12 agonist failure given vedolizumab also had a CDAI-100 response (>/=100-point decrease in CDAI score f

13 d 25.7% of the patients, respectively, had a CDAI-100 response (>/=100-point decrease in the CDAI sco

14 iving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response t

15 ity Index [CDAI] score of >/=100 points or a CDAI score <150).

16 come in both trials was disease remission (a CDAI score of less than 150).

17 All patients went into remission with a CDAI less than 150.

18 e (P<.0001 for both), the 33 patients with a CDAI of at least 150 (P<.032 and P<.0074, respectively),

19 sponding to high levels of disease activity (CDAI/SDAI) or moderate levels of disease activity (DAS/D

20 In ADVANCE, CDAI clinical remission rate was 45% (adjusted differenc

21 ve inflammation at histopathologic analysis (CDAI score, 261 vs 251, respectively [P = .77]; HBI scor

22 re set measure thresholds, SDAI <or=3.3, and CDAI <or=2.8.

23 D and CRP (r = 0.525), fCal (r = 0.450), and CDAI (r = 0.407), while a weak correlation was found wit

24 endoscopy (VCE), CRP, fecal calprotectin and CDAI.

25 001) of CD recurrence, but the CRP level and CDAI score did not.

26 moderate positive correlation between PE and CDAI (r=0.65, p<0.001).

27 Symptoms and CDAI improved before hospital discharge, whereas radiogr

28 al management group after random assignment: CDAI decrease of <100 points compared with baseline or C

29 l management group before random assignment: CDAI decrease of <70 points compared with baseline or CD

30 Time-averaged CDAI also showed a better fit.

31 41-0.997 per year; p=0.048) and low baseline CDAI (0.82, 0.74-0.98 per 10 units; p=0.031).

32 The mean DAS, DAS28, CDAI score, and SDAI score were 3.7, 4.7, 30.8, and 36.4

33 abilities were seen between the DAS, DAS28, CDAI, and SDAI for the ACR pediatric criteria for improv

34 responded to low disease activity (DAS/DAS28/CDAI) or moderate disease activity (SDAI).

35 (ii) Both treatments decreased CDAI, increased IBDQ scores, and normalized the ReHo val

36 enerated for mean normalized iodine density, CDAI, and HBI to determine sensitivity, specificity, and

37 ubgroups of patients with respect to gender, CDAI scores, disease location, clinical behavior (obstru

38 ool, through copper-directed acyl imidazole (CDAI) chemistry.

39 The study's primary endpoint was change in CDAI at week 2.

40 Response to infliximab as median change in CDAI was placebo (least response) < perinuclear ANCA (pA

41 Overall, 12 patients had a decrease in CDAI of more than 100 points, and eight achieved clinica

42 CDAI-100 response (>/=100-point decrease in CDAI score from baseline) at week 6 than those given pla

43 Decreases in CDAI score by 70 or more and 100 or more points (seconda

44 luminal disease was defined as reduction in CDAI score of >150 points and for fistula patients was 2

45 ith a statistically significant reduction in CDAI.

46 defined by a Crohn's Disease Activity Index (CDAI) < 150, underwent a gastric emptying test by breath

47 cal remission (Crohn Disease Activity Index (CDAI) <150 [range, 0-600]), no use of corticosteroids or

48 levels, and Crohn's Disease Activity Index (CDAI) and Inflammatory Bowel Disease Questionnaire (IBDQ

49 assessed by Crohn's disease activity index (CDAI) and simple clinical colitis index (SCCAI) for CD a

50 oints in the Crohn's Disease Activity Index (CDAI) at the end of treatment (day 57).

51 week 12 and Crohn's Disease Activity Index (CDAI) clinical remission at week 52 (CDAI clinical remis

52 Crohn's Disease Activity Index (CDAI) data from the North American patients in the clini

53 s or more in Crohn's Disease Activity Index (CDAI) from baseline to week 6.

54 ) defined as a Crohn Disease Activity Index (CDAI) greater than 250, and/or Crohn Severity Index grea

55 , defined by a Crohn Disease Activity Index (CDAI) higher than 250 despite anti-tumor necrosis factor

56 reduction in Crohn's Disease Activity Index (CDAI) of 100 points, was observed in 40% of patients at

57 h ulcers), a Crohn's Disease Activity Index (CDAI) of 150-450 depending on dose of prednisone at base

58 defined as a Crohn's Disease Activity Index (CDAI) of 220-450, with mucosal ulcers in the ileum or co

59 f age with a Crohn's Disease Activity Index (CDAI) of 250-400 despite conventional therapies includin

60 e also used clinical disease activity index (CDAI) or data in the BeSt study (European population).

61 t 220 on the Crohn's disease activity index (CDAI) received a 5 mg/kg intravenous infusion of inflixi

62 <or=11 and Clinical Disease Activity Index (CDAI) score <or=10.

63 ease in mean Crohn's disease activity index (CDAI) score during treatment (p<0.0001).

64 isease and a Crohn's Disease Activity Index (CDAI) score of 220-450, who had not responded to or were

65 rease in the Crohn's Disease Activity Index (CDAI) score of at least 70 points, at week 10.

66 defined as a Crohn's Disease Activity Index (CDAI) score of less than 150, with maintenance of remiss

67 with active CD, based on CD activity index (CDAI) scores >220 and mucosal ulcerations, who received

68 atients with Crohn's Disease Activity Index (CDAI) scores of > or = 250 and < or = 500 despite > or =

69 n (CRP), and Crohn's disease activity index (CDAI) scores were measured before surgery and then at 6,

70 estinal, the Crohn's Disease Activity Index (CDAI) was used to assess response.

71 activity (CICDA), (b) the CD activity index (CDAI), and (c) the simplified endoscopic score for CD (S

72 Crohn's disease activity index (CDAI), C-reactive protein, fecal calprotectin, and micro

73 ing indexes: Crohn's disease activity index (CDAI), fCal, serum C-reactive protein (CRP), and haemogr

74 YO score and CD using the CD activity index (CDAI).

75 red with the Crohn's Disease Activity Index (CDAI).

76 inflammation and clinical CD activity index (CDAI).

77 I), and the Clinical Disease Activity Index (CDAI).

78 n's disease (Crohn's Disease Activity Index [CDAI] > 200 and/or draining perianal disease) initiated

79 n's disease (Crohn's Disease Activity Index [CDAI] > or =151 and < or =450) received a 3-mg/kg infusi

80 after HSCT (Crohn's Disease Activity Index [CDAI] <150).

81 ivity indexes (Crohn Disease Activity Index [CDAI] and Harvey-Bradshaw Index [HBI]) were compared wit

82 l remission (Crohn's disease activity index [CDAI] in the US protocol, or stool frequency and abdomin

83 score on the Crohn's Disease Activity Index [CDAI] of </=150, with scores ranging from 0 to approxima

84 core for the Crohn's Disease Activity Index [CDAI] of at least 100 points) and remission (defined by

85 (defined by Crohn's disease activity index [CDAI] or patient-reported outcome criteria [average dail

86 eline in the Crohn's Disease Activity Index [CDAI] score of >/=100 points or a CDAI score <150).

87 3 months of active CD (a CD Activity Index [CDAI] score of 220-450, a simple endoscopic score for CD

88 ly to severely active CD (CD activity index [CDAI] score, 220-400 points) were assigned randomly to g

89 Index, HBI; Crohn's disease activity index, CDAI and paediatric CDAI, PCDAI).

90 n >/=250 mug/g, C-reactive protein >/=5mg/L, CDAI >/=150, or prednisone use in the previous week; cli

91 ciated with less surgeries and lower maximal CDAI and a similar trend was observed for rs55646866 and

92 ee SNPs was negatively correlated to maximal CDAI.

93 After 8 weeks of treatment, mean CDAI had fallen by 190 points.

94 The initial median CDAI was 291 (range, 250-358).

95 The median CDAI score at entry was 371 (95-468).

96 The median CDAI score was 175 (30-468; P < 0.001 vs. baseline).

97 corresponded to low (DAS/DAS28) or moderate (CDAI/SDAI) disease activity.

98 In MOTIVATE, CDAI clinical remission rate was 42% (22%, 13-31; 80/191

99 Higher rates of CDAI clinical remission and endoscopic response (but not

100 In this group, remission (based on CDAI </=150) was observed in 3 of 8 patients (38%) at we

101 ase of <100 points compared with baseline or CDAI >/=200, or prednisone use in the previous week).

102 ease of <70 points compared with baseline or CDAI >200; clinical management group after random assign

103 ence with greater accuracy than CRP level or CDAI score.

104 disease activity either Mayo score of UC or CDAI of CD.There was significant correlation to the exte

105 disease activity index, CDAI and paediatric CDAI, PCDAI).

106 hed with 360 mg risankizumab versus placebo (CDAI clinical remission was reached in 74 (52%) of 141 p

107 mg versus withdrawal (subcutaneous placebo; CDAI clinical remission reached in 87 [55%] of 157 patie

108 nce to MED over time correlated with reduced CDAI and inflammatory markers (P < .05).

109 ibustion group, were correlated with reduced CDAI.

110 The primary outcome was clinical remission (CDAI <150) at week 12 (intention-to-treat population).

111 of patients who were in clinical remission (CDAI score <150) at week 52 in the intention-to-treat po

112 e in corticosteroid-free clinical remission (CDAI score <150), respectively.

113 roportion of patients in clinical remission (CDAI, </=150 points) at week 6.

114 Patients have remained in remission (CDAI < 100) for 1 year since HSCT.

115 The percentage of patients in remission (CDAI < 150), steroid-free, or medication-free at any pos

116 o responded at week 2 and were in remission (CDAI <150) at week 30 and the time to loss of response u

117 The CDAI score decreased from 270 points (preinfusion) to 13

118 At week 2, the CDAI decreased significantly from baseline after infusio

119 from baseline of at least 100 points in the CDAI score on day 57 (48 percent vs. 26 percent, P=0.01)

120 d by a decrease of at least 70 points in the CDAI score on day 57 between the sargramostim and placeb

121 I-100 response (>/=100-point decrease in the CDAI score) (P=0.23).

122 as a reduction of 100 points or more in the CDAI score) at day 28.

123 d an additional infusion at week 10 if their CDAI score had not decreased by 70 points.

124 Clinical remission was defined as a total CDAI < 150 (luminal patients) or >/=2+ for all parameter

125 At first visit and follow up, CDAI and FCP were positively correlated (r-0.689, p- 0.0

126 l regions were significantly correlated with CDAI score decreases.

127 ted CD course, and inversely correlated with CDAI, fecal calprotectin, C-reactive protein, and microb

128 isease detected in LDCTE and correlates with CDAI.